Sheridan Carrington, PhD
About Sheridan Carrington, PhD
Sheridan Carrington, PhD, is the Director of Global Drug Development at Bristol Myers Squibb in Princeton, New Jersey. He has extensive experience in drug development, business development, and translational sciences, with a strong background in molecular physiology and biophysics.
Company
Sheridan Carrington, PhD, currently works at Bristol Myers Squibb as the Director of Global Drug Development. Bristol Myers Squibb is a renowned biopharmaceutical company based in Princeton, New Jersey, United States, focusing on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.
Title
Sheridan Carrington holds the title of Director, Global Drug Development at Bristol Myers Squibb. In this role, Sheridan oversees various aspects of drug development, including clinical development, regulatory affairs, and medical safety.
Education and Expertise
Sheridan Carrington earned a Doctor of Philosophy (PhD) in Molecular Physiology & Biophysics from Vanderbilt University, where Sheridan studied from 2013 to 2019. Prior to this, Sheridan completed a Bachelor of Basic Medical Science in Pharmacology at The University of the West Indies, Mona, from 2008 to 2011. Sheridan has developed expertise in financial modeling, contract negotiation, intellectual property management, and deep dive therapeutics analysis.
Professional Background
Sheridan Carrington has a diverse professional background with experience in various sectors of the pharmaceutical and biotechnology industries. Prior to the current role at Bristol Myers Squibb, Sheridan worked at Avalo Therapeutics in Wayne, Pennsylvania as the Director of Business Development for two months in 2022, and as a Research Analyst in Translational Sciences from 2020 to 2022. Sheridan also served as Program Manager at the University of Pennsylvania School of Medicine's Orphan Disease Center from 2019 to 2020. Sheridan's earlier roles include a Summer Analyst at Great Point Partners, Visiting Graduate Student at the University of Michigan, and Licensing Intern at Vanderbilt University Center for Technology Transfer and Commercialization.
Specific Projects and Initiatives
During the career, Sheridan Carrington participated in the AUTM Burroughs Wellcome Fund Technology Transfer Training Program from 2016 to 2017. Additionally, Sheridan completed a two-year leadership development program featuring rotations across global drug development functions, including clinical development, regulatory, and medical safety. These initiatives have significantly contributed to Sheridan's expertise and professional growth in the field of drug development.